EUVIMEDEUVIMED entdecken
Crossref

Semaglutide alters gut microbiota and improves NAFLD in db/db mice

Tuohua Mao, Chenxuan Zhang, Shuang Yang, Yingying Bi, Man Li, Jia Yu

Biochemical and Biophysical Research Communications · 2024-05 · 710 · 149882

DOI: 10.1016/j.bbrc.2024.149882 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2024-05. Verfasst von Tuohua Mao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Renmin Hospital of Wuhan University, Wuhan, 430060, PR China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2, Gastrointestinal Microbiome, Glucagon-Like Peptides. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease associated with type 2 diabetes mellitus (T2D). NAFLD can progress to nonalcoholic steatohepatitis (NASH), cirrhosis, and even cancer, all of which have a very poor prognosis. Semaglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist, has been recognized as a specific drug for the treatment of diabetes. In this study, we used a gene mutation mouse model (db/db mice) to investigate the potential liver-improving effects of semaglutide. The results showed that semaglutide improved lipid levels and glucose metabolism in db/db mice. HE staining and oil red staining showed alleviation of liver damage and reduction of hepatic lipid deposition after injection of semaglutide. In addition, semaglutide also improved the integrity of gut barrier and altered gut microbiota, especially Alloprevotella, Alistpes, Ligilactobacillus and Lactobacillus. In summary, our findings validate that semaglutide induces modifications in the composition of the gut microbiota and ameliorates NAFLD, positioning it as a promising therapeutic candidate for addressing hepatic steatosis and associated inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2Gastrointestinal MicrobiomeGlucagon-Like PeptidesMiceAnimalsLiverLipidsMice, Inbred C57BLSemaglutide

Stichwörter der Autor:innen

GLP-1Gut microbiotaHepaticNAFLDSemaglutide

Substanzen

LipidsGlucagon-Like PeptidesSemaglutide

Autor:innen und Institutionen

  • Department of Endocrinology, Renmin Hospital of Wuhan University, Wuhan, 430060, PR China.
  • Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, PR China.
  • Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, PR China.
  • Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, PR China. Electronic address: liman192@whu.edu.cn.
  • Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, PR China. Electronic address: yogaqq116@whu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Mao, T., Zhang, C., Yang, S., Bi, Y., Li, M., & Yu, J. (2024). Semaglutide alters gut microbiota and improves NAFLD in db/db mice. Biochemical and Biophysical Research Communications, 710, 149882. https://doi.org/10.1016/j.bbrc.2024.149882

Vancouver

Mao T, Zhang C, Yang S, Bi Y, Li M, Yu J. Semaglutide alters gut microbiota and improves NAFLD in db/db mice. Biochemical and Biophysical Research Communications. 2024;710:149882. doi:10.1016/j.bbrc.2024.149882

BibTeX
@article{Mao2024,
  author = {Mao, Tuohua and Zhang, Chenxuan and Yang, Shuang and Bi, Yingying and Li, Man and Yu, Jia},
  title = {Semaglutide alters gut microbiota and improves NAFLD in db/db mice},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2024},
  volume = {710},
  pages = {149882},
  doi = {10.1016/j.bbrc.2024.149882}
}
Kostenlos starten →